Last reviewed · How we verify

Renal Disease with Edema — Treatment Landscape & Competitive Intelligence

Renal Disease with Edema (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Renal Disease with Edema, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Zaroxolyn METOLAZONE I3 Pharms Thiazide-like Diuretic [EPC] Carbonic anhydrase 7 1973-01-01
Torasemide Torasemide Medical University of Warsaw Solute carrier family 12 member 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 2 drugs in Renal Disease with Edema
  2. I3 Pharms · 1 drug in Renal Disease with Edema
  3. Medical University of Warsaw · 1 drug in Renal Disease with Edema

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Renal Disease with Edema:

Cite this brief

Drug Landscape (2026). Renal Disease with Edema — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/renal-disease-with-edema. Accessed 2026-06-11.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing